An optical coherence tomography study of two new generation stents with 2 biodegradable polymer carrier, eluting paclitaxel vs. biolimus-A9

dc.contributor.authorDavlouros, Periklis
dc.contributor.authorMavronasiou, Eleni
dc.contributor.authorXanthopoulou, Ioanna
dc.contributor.authorKarantalis, Vasileios
dc.contributor.authorTsigkas, Grigorios
dc.contributor.authorHahalis, George
dc.contributor.authorAlexopoulos, Dimitrios
dc.contributor.otherΔαβλούρος, Περικλής
dc.contributor.otherΜαυρονάσιου, Ελένη
dc.contributor.otherΚαρανταλής, Βασίλειος
dc.contributor.otherΤσίγκας, Γρηγόριος
dc.contributor.otherΧαλάλης, Γεώργιος
dc.contributor.otherΞανθοπούλου, Ιωάννα
dc.contributor.otherΑλεξόπουλος, Δημήτριος
dc.date.accessioned2019-02-01T19:09:48Z
dc.date.available2019-02-01T19:09:48Z
dc.date.copyright2011-11
dc.description.abstractBackground: Tissue coverage and strut apposition of drug eluting stents (DES), which can be assessed with 21 optical coherence tomography (OCT), may be associated with late stent thrombosis (LST). 22 Methods: Prospective observational angiographic and OCT follow-up at 6 months post-implantation of a 23 biolimus-A9 eluting stent (BES) vs. a paclitaxel eluting stent (PES), with biodegradable polymer carriers. The 24 primary outcome was the percent difference of uncovered struts between BESs and PESs. 25 Results: A maximum likelihood model was used for analysis, to account for data clustering. Sixteen patients 26 were treated with BES (28 lesions/4530 struts) and 16 with PES (23 lesions/4450 struts). Overall, BESs 27 compared to PESs had more uncovered [0.41% vs. 0.21%, difference estimate (DE) 0.2 (95% CI, 0.06–0.34), 28 p=0.006], malapposed [0.18% vs. 0.04%, DE 0.14 (95% CI 0.05–0.23), p=0.003], uncovered and malapposed 29 [0.08% vs. 0.026%, DE 0.057 (95% CI 0.015–0.1), p=0.01] and protruding struts [0.23% vs. 0.04%, DE 0.185 (95% 30 CI 0.1–0.27), pb0.001], and significantly lower neointimal thickness (59.3± 28.2 μm vs. 201.7± 97.5, 31 pb0.001). None of the BESs was totally covered with neointima, in contrast to 5 (21.7%) PESs (p=0.01). 32 Thrombus was detected in 1 (3.6%) BES and 5 (21.7%) PESs (p=0.05); however, no patient experienced 33 clinical stent thrombosis. 34 Conclusion: Between two stents with biodegradable polymer, OCT demonstrated that BESs had more 35 uncovered and malapposed struts compared to PESs at 6 months. This difference might be partly attributed to 36 the more potent antiproliferative properties of biolimus-A9; however, its impact on clinical outcome and on 37 the risk of LST is yet to be determined.el
dc.description.translatedabstract--el
dc.identifierDavlouros P.A., Mavronasiou E., Xanthopoulou I., Karantalis V., Tsigkas G., Hahalis G., Alexopoulos D. (2012), 'An optical coherence tomography study of two new generation stents with biodegradable polymer carrier, eluting paclitaxel vs. biolimus-A9', International Journal of Cardiology, 157:3, pp. 341-346. Preprintel
dc.identifier.urihttps://doi.org/10.1016/j.ijcard.2010.12.072el
dc.identifier.urihttp://hdl.handle.net/10889/11912
dc.language.isoenel
dc.sourceInternational Journal of Cardiologyel
dc.subjectOptical coherence tomography (OCT)el
dc.subjectPaclitaxelel
dc.subjectBiolimus-A9el
dc.subjectNeointimal coverageel
dc.subjectMalappositionel
dc.subject.alternativeΟπτική τομογραφία συνοχήςel
dc.subject.alternativeΠακλιταξέληel
dc.titleAn optical coherence tomography study of two new generation stents with 2 biodegradable polymer carrier, eluting paclitaxel vs. biolimus-A9el
dc.typeJournal (paper)el
dcterms.extent341-6el

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Davlouros-Mavronasiou(med)_International Journal of Cardiology.pdf
Size:
5.46 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
5.38 KB
Format:
Item-specific license agreed upon to submission
Description: